Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.01% | -12.07% | -19.79% | -15.71% | -107.16% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.49% | 10.06% | 24.61% | 21.85% | 12.93% |
| Change in Net Operating Assets | -111.96% | 2,586.27% | -113.52% | 217.06% | 72.78% |
| Cash from Operations | -120.54% | 37.47% | -44.98% | 19.71% | -25.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 219,858.10% | -56.61% | -30.66% | 420.90% | -99.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10,435.71% | -- | -- | 100.00% | -114.45% |
| Cash from Financing | 438,326.53% | -120.25% | -30.66% | 129.03% | -101.61% |
| Foreign Exchange rate Adjustments | 97.54% | -179.22% | 812.96% | -1,700.00% | -300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,757.33% | 18.66% | -32.22% | 34.89% | -111.49% |